Donanemab in Early Symptomatic Alzheimer Disease

This randomized, double-blind, placebo-controlled, 18-month phase 3 trial enrolled 1736 participants with early symptomatic Alzheimer disease (mild cognitive impairment/mild dementia) with amyloid and low/medium or high tau pathology based on positron emission tomography imaging from June 2020 to November 2021 to assess efficacy and adverse events of donanemab.